Affiliate Disclosure: This page contains affiliate links. We may earn a commission when you sign up — at no additional cost to you. Read our full disclosure.
GLP-1 receptor agonist used for type 2 diabetes (Ozempic), chronic weight management with cardiovascular risk reduction (Wegovy), and oral type 2 diabetes (Rybelsus).
By Novo NordiskUpdated 2026-05-25
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-05-25
Semaglutide overview
GLP-1 receptor agonist used for type 2 diabetes (Ozempic), chronic weight management with cardiovascular risk reduction (Wegovy), and oral type 2 diabetes (Rybelsus).
Semaglutide at a glance
Manufacturer
Novo Nordisk
FDA status
FDA-approved
Pivotal trials
STEP-1 (NEJM 2021, PMID 33567185) — 14.9% mean weight loss at 2.4 mg / 68 weeks
SELECT (NEJM 2023, PMID 37952131) — 20% MACE reduction in non-diabetic adults with overweight/obesity + CVD
FLOW (NEJM 2024, PMID 38785189) — 24% reduction in major kidney/CV events in T2D + CKD
SURPASS-2 (NEJM 2021, PMID 34170647) — head-to-head: tirzepatide ~47% greater weight loss vs semaglutide 1 mg